Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Greece

Research and Innovation Action · Running

Project-COMFORT Patient-Centric blOod saMpling FOr impRoved healThcare (Project-COMFORT)

Coordinator
Aristotelio Panepistimio Thessalonikis, Greece
Runs
1 November 2024 to 30 April 2028
Status
Running
EU funding
€3.0m
Total cost
€6.7m
Partners
56 organisations in 13 countries
Type
Research and Innovation Action
Grant agreement
101163781

What the project is doing

In the project's own words, from its summary on CORDIS.

BackgroundHealth systems face a time of unprecedented change, with spiraling costs, increasing cultural disparity in access to healthcare and research, and an infrastructure that is decades old. Today, telehealth is a realistic alternative making care and research more accessible and personalised with less burden to better support the most vulnerable and under-served in our society. The ability to test and monitor for illnesses using Patient Centric micro-Sampling (PCmS) is at the centre of this reform.

Aim and main objectivesThis project is designed to build upon existing pilots and knowledge, then collaborate cross-sectorially to co-create and test the logistics, infrastructure and tools required to make PCmS a core healthcare tool and an acceptable alternative to venous blood-draw across Europe. This project aligns with many IHI’s objectives focusing on cross-sectorial collaboration, emphasizing patient and end-user- centric co-design of outputs, harmonised regulatory and data generation approaches enhancing the potential of digital innovations in healthcare, while aiming to reduce the environmental footprint during the project and in final outputs to ensure that the expected long-term impact is a reachable reality that will deliver significant benefit to the community and address unmet public health needs at scale.

To achieve our objectives, we bring together a broad group of required expertise, know-how and end-users (i.e., public and patients) to form a public-private-partnership specifically equipped to tackle this challenge. This collaborative approach where the relevant stakeholders such as healthcare professionals, regulatory agencies and patients are involved and integrated to deliver solutions and innovation across healthcare systems and ensure the best chances for success and long-term positive impact from this project.

Key deliverables include:1)An optimized, tested and validated ‘Gold Standard’ infrastructure and workflow for PCmS across Europe as a proven and reliable alternative to venipuncture2)Harmonised and clear regulatory and HTA pathways, standards and acceptability, measures and cost-benefit models across Europe3)Documented evidence to draw a citable ‘line in the sand’ for future research to support decisions to integrate PCmS into decentralised trials and care pathways4)Stakeholder engagement and patient involvement models and research on preferences and acceptability for PCmS5)Foundation for future: Enable access to the developed PCmS scientific findings, tools and assessment measures for rapid uptake and integration of PCmS approaches into decentralised clinical studies and healthcareExpected impact:-Patient-centric microsampling becomes an accepted alternative to the current standard of care venipuncture and the data gathered can be leveraged in healthcare planning.-Lowered patient burden and lowered barrier to access in situations where blood samples need to be collected, whether as part of diagnosis, care plan, health monitoring etc. -A solution to leverage high amounts of data gathered from increased testing can be explored already in this project so that it can pave the way for future research that can improve health outcomes.

Who is involved

OrganisationCityCountryRole
Aristotelio Panepistimio ThessalonikisThessalonikiGreeceCoordinator
European Centre for Clinical Research TrainingBruxelles / BrusselBelgiumParticipant
Glaxosmithkline Biologicals SARixensartBelgiumAssociatedpartner
Iqvia Solutions BelgiumZaventemBelgiumParticipant
Janssen Pharmaceutica NVBeerseBelgiumParticipant
F. Hoffmann-La Roche AGBaselSwitzerlandParticipant
Novartis Pharma AGBaselSwitzerlandParticipant
Roche Diagnostics International AGRotkreuzSwitzerlandAssociatedpartner
Univerzita Palackeho V OlomouciOlomoucCzechiaParticipant
Bayer AktiengesellschaftLeverkusenGermanyParticipant
Jones Lang Lasalle SeFrankfurt Am MainGermanyParticipant
Lilly Deutschland GmbHBad HomburgGermanyAssociatedpartner
Miebach Consulting GmbHFrankfurt Am MainGermanyParticipant
Siemens Healthineers AGForchheimGermanyParticipant
Collaborate Healthcare- Kainotomes Ypiresies Ygeias IkePaiania AttikiGreeceParticipant
Thetabiomarkers IkeThessalonikiGreeceParticipant
Fundacio Hospital Universitari Vall D'hebron - Institut De RecercaBarcelonaSpainParticipant
Fundacio Institut Universitari Pera La Recerca a L'atencio Primaria De Salut Jordi Gol I GurinaBarcelonaSpainParticipant
Fundacio Privada per a La Recerca I La Docencia Sant Joan De DeuEsplugues De LlobregatSpainParticipant
Fundacion Para La Investigacion De Malaga En Biomedicina Y SaludMalagaSpainParticipant
Hospital Sant Joan De DeuEsplugues De LlobregatSpainThird party
Institut Catala De La SalutBarcelonaSpainThird party
Servicio Andaluz De SaludSevillaSpainThird party
Becton Dickinson France SASLe Pont De ClaixFranceParticipant
Euraxi PharmaJoue les ToursFranceParticipant
Institut De Recherches Internationales ServierGif-Sur-YvetteFranceParticipant
Institut PasteurParisFranceParticipant
Institut Servier D'innovation TherapeutiqueGif-Sur-YvetteFranceAssociatedpartner
Technologie ServierOrleansFranceAssociatedpartner
Eli Lilly Kinsale LtdCorkIrelandAssociatedpartner
Bayer SpAMilanItalyAssociatedpartner
Pharma Quality Europe SRLReggelloItalyParticipant
Stichting VuAmsterdamNetherlandsParticipant
Stichting Sanquin BloedvoorzieningAmsterdamNetherlandsParticipant
Astrazeneca ABSodertaeljeSwedenParticipant
Capitainer ABSolnaSwedenParticipant
International Doping Tests Management AB IdtmStockholmSwedenParticipant
Karolinska InstitutetStockholmSwedenParticipant
Region StockholmStockholmSwedenParticipant
Bayer Public Limited CompanyNewburyUnited KingdomAssociatedpartner
Glaxosmithkline Research & Development LimitedLondonUnited KingdomParticipant
Labcorp Early Development Laboratories LimitedHarrogateUnited KingdomParticipant
Medipace LimitedLondonUnited KingdomAssociatedpartner
Patient Centric Sampling Interest Group CicWareUnited KingdomAssociatedpartner
Pfizer LimitedSandwichUnited KingdomAssociatedpartner
Pfizer R&D UK LimitedSandwichUnited KingdomAssociatedpartner
Trajan Scientific Europe LtdMilton KeynesUnited KingdomAssociatedpartner
University of DundeeDundeeUnited KingdomAssociatedpartner
University of Newcastle Upon TyneNewcastle Upon TyneUnited KingdomAssociatedpartner
Abbvie IncNorth Chicago IlUnited StatesParticipant
Eli Lilly and CompanyIndianapolisUnited StatesParticipant
Pfizer IncNew York CityUnited StatesParticipant
Q Squared Solutions LLCRaleighUnited StatesAssociatedpartner
Rhinostics, Inc.WalthamUnited StatesAssociatedpartner
Tasso IncSeattleUnited StatesAssociatedpartner
YourBio Health, Inc.Medford, MAUnited StatesAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI